AU2007322075B2 - Methods of enhancing immune response using electroporation-assisted vaccination and boosting - Google Patents

Methods of enhancing immune response using electroporation-assisted vaccination and boosting Download PDF

Info

Publication number
AU2007322075B2
AU2007322075B2 AU2007322075A AU2007322075A AU2007322075B2 AU 2007322075 B2 AU2007322075 B2 AU 2007322075B2 AU 2007322075 A AU2007322075 A AU 2007322075A AU 2007322075 A AU2007322075 A AU 2007322075A AU 2007322075 B2 AU2007322075 B2 AU 2007322075B2
Authority
AU
Australia
Prior art keywords
tissue
muscle
skin
electroporation
boosting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2007322075A
Other languages
English (en)
Other versions
AU2007322075A1 (en
Inventor
Rune Kjeken
Feng Lin
Iacob Mathiesen
Dietmar Rabussay
Elisabeth Torunn Tjelle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genetronics Inc
Original Assignee
Genetronics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetronics Inc filed Critical Genetronics Inc
Publication of AU2007322075A1 publication Critical patent/AU2007322075A1/en
Priority to AU2013206520A priority Critical patent/AU2013206520B2/en
Application granted granted Critical
Publication of AU2007322075B2 publication Critical patent/AU2007322075B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2007322075A 2006-11-17 2007-11-16 Methods of enhancing immune response using electroporation-assisted vaccination and boosting Ceased AU2007322075B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2013206520A AU2013206520B2 (en) 2006-11-17 2013-06-25 Methods of enhancing immune response using electroporation-assisted vaccination and boosting

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85972406P 2006-11-17 2006-11-17
US60/859,724 2006-11-17
PCT/US2007/024051 WO2008063555A2 (en) 2006-11-17 2007-11-16 Methods of enhancing immune response using electroporation-assisted vaccination and boosting

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2013206520A Division AU2013206520B2 (en) 2006-11-17 2013-06-25 Methods of enhancing immune response using electroporation-assisted vaccination and boosting

Publications (2)

Publication Number Publication Date
AU2007322075A1 AU2007322075A1 (en) 2008-05-29
AU2007322075B2 true AU2007322075B2 (en) 2013-07-25

Family

ID=39430332

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2007322075A Ceased AU2007322075B2 (en) 2006-11-17 2007-11-16 Methods of enhancing immune response using electroporation-assisted vaccination and boosting

Country Status (8)

Country Link
US (1) US20100285040A1 (cg-RX-API-DMAC7.html)
EP (1) EP2091558B1 (cg-RX-API-DMAC7.html)
JP (1) JP5646851B2 (cg-RX-API-DMAC7.html)
KR (1) KR20090080941A (cg-RX-API-DMAC7.html)
CN (1) CN101522211A (cg-RX-API-DMAC7.html)
AU (1) AU2007322075B2 (cg-RX-API-DMAC7.html)
CA (1) CA2668649A1 (cg-RX-API-DMAC7.html)
WO (1) WO2008063555A2 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120130150A1 (en) 2009-06-24 2012-05-24 International Scientific Pty Ltd. apparatus and method of treatment utilizing a varying electromagnetic energization profile
KR101723605B1 (ko) * 2014-10-21 2017-04-07 진원생명과학 주식회사 대상포진 예방 및 치료용 dna 백신 조성물 및 이를 이용한 vzv 항원에 대한 t세포 활성화 방법
US10233419B2 (en) 2016-06-30 2019-03-19 Zymergen Inc. Apparatuses and methods for electroporation

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241140A1 (en) * 2000-11-01 2004-12-02 Pavlakis George N. Expression vectors able to elicit improved immune response and methods of using same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US118956A (en) * 1871-09-12 Improvement in apparatus for the manufacture of extracts from hemlock and other
US5273525A (en) 1992-08-13 1993-12-28 Btx Inc. Injection and electroporation apparatus for drug and gene delivery
US6009345A (en) 1992-08-17 1999-12-28 Genetronics, Inc. Method and apparatus for a combination of electroporation and iontophoresis for the delivery of drugs and genes
US5439440A (en) 1993-04-01 1995-08-08 Genetronics, Inc. Electroporation system with voltage control feedback for clinical applications
US6261281B1 (en) 1997-04-03 2001-07-17 Electrofect As Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
WO1998043702A2 (en) 1997-04-03 1998-10-08 Iacob Mathiesen Method for introducing pharmaceutical drugs and nucleic acids into skeletal muscle
TW368420B (en) 1997-11-04 1999-09-01 Genetronics Inc Apparatus and method for transdermal molecular delivery by applying sufficient amplitude of electric field to induce migration of molecules through pores in the stratum corneum
US6972013B1 (en) 1998-07-13 2005-12-06 Genetronics, Inc. Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
WO2000045823A1 (en) * 1999-02-08 2000-08-10 Chiron Corporation Electrically-mediated enhancement of dna vaccine immunity and efficacy in vivo
US7171264B1 (en) * 1999-05-10 2007-01-30 Genetronics, Inc. Intradermal delivery of active agents by needle-free injection and electroporation
GB9922361D0 (en) * 1999-09-21 1999-11-24 Isis Innovation Generating an immune response to an antigen
CA2478614C (en) 2001-03-13 2013-01-15 University Of South Florida Electromanipulation device and method
BR0214280A (pt) * 2001-11-19 2005-01-11 Becton Dickinson Co Composição farmacêuticas em forma particulada
MXPA04005770A (es) * 2001-12-14 2005-05-17 Genetronics Inc Metodos para la inmunizacion con polinucleotidos asistida por particulas utilizando un campo electrico de impulsos.
JP4705591B2 (ja) * 2004-01-07 2011-06-22 バイオメディカル リサーチ モデルズ, インコーポレイテッド 抗原または免疫原に対する免疫応答を仕立てる方法。
CA3063263C (en) 2006-02-11 2024-01-16 Genetronics, Inc. Device and method for single-needle in vivo electroporation

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040241140A1 (en) * 2000-11-01 2004-12-02 Pavlakis George N. Expression vectors able to elicit improved immune response and methods of using same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BABIUK S., et al., Electroporation improves the efficacy of DNA vaccines in large animals, Vaccine, 2002, Vol. 2, pg. 3399-3404 *
ZHANG L., et al., Enhancement of the effectiveness of electroporation-augmented cutaneous DNA vaccination by a particulate adjuvant, Bioelectrochemistry, 2004, Vol. 63, pg 369-373 *

Also Published As

Publication number Publication date
WO2008063555A2 (en) 2008-05-29
EP2091558A4 (en) 2012-07-04
EP2091558B1 (en) 2018-04-04
JP5646851B2 (ja) 2014-12-24
CA2668649A1 (en) 2008-05-29
US20100285040A1 (en) 2010-11-11
CN101522211A (zh) 2009-09-02
EP2091558A2 (en) 2009-08-26
JP2010510218A (ja) 2010-04-02
KR20090080941A (ko) 2009-07-27
WO2008063555A3 (en) 2008-11-06
AU2007322075A1 (en) 2008-05-29

Similar Documents

Publication Publication Date Title
JP7141063B2 (ja) 抗原およびアジュバントとしてのインターロイキン-21を有するワクチン
Kisakov et al. The use of electroporation to deliver DNA-based vaccines
CN1253220C (zh) 通过微管在真皮内输入疫苗和基因治疗剂
CN104168912B (zh) 促进剂-dna组合疫苗
JP7011241B2 (ja) Wt1ワクチン
WO2001085202A2 (en) Electroporation for introduction of molecules into cells
CN103717249A (zh) 注射针和装置
MX2011012807A (es) Composiciones y metodos para administracion de vacunas contra virus del dengue.
Dobaño et al. Enhancement of antibody and cellular immune responses to malaria DNA vaccines by in vivo electroporation
US20130005028A1 (en) Activation of RIG-I Pathway
US11097099B2 (en) Multiple tissue layer electroporation applicator and device
EP2091558B1 (en) Methods of enhancing immune response using electroporation-assisted vaccination and boosting
WO2025261301A1 (zh) 一种抗原抗体复合物及其制备方法和应用
US20240009300A1 (en) Dna encoded nanoparticles and method of use thereof as a coronavirus disease 2019 (covid-19) vaccine
AU2013206520B2 (en) Methods of enhancing immune response using electroporation-assisted vaccination and boosting
US20250255954A1 (en) Stabilized spike protein and method of use thereof as a coronavirus disease 2019 (covid-19) vaccine
US11179458B2 (en) Immunogenicity of an optimized synthetic consensus DNA vaccine for porcine epidemic diarrhea virus
HK1135848A (en) Methods of enhancing immune response using electroporation-assisted vaccination and boosting
WO2024182700A2 (en) Glycan modified sars-cov-2 glycoprotein nanoparticles and methods of use thereof
US20230321230A1 (en) Compositions and Methods for Adjuvanted Vaccines
WO2025038695A1 (en) Modified h3 hemagglutinin antigens and methods of use thereof
US20190307704A1 (en) Method for enhanced delivery of gene based therapy and vaccination using electroporation
Gill et al. Immunization Via Skin Using Vaccine-Coated Microneedles

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired